Search results
Results from the WOW.Com Content Network
Streptokinase is a thrombolytic medication activating plasminogen by nonenzymatic mechanism. [1] As a medication it is used to break down clots in some cases of myocardial infarction (heart attack), pulmonary embolism , and arterial thromboembolism . [ 2 ]
Anistreplase is a thrombolytic drug. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC). As a thrombolytic drug, ...
Common side effects include pain associated with injection site reactions, injection site bruising, upper respiratory infection, headache, rash, myalgia, dizziness, and diarrhea. [ 12 ] The US Food and Drug Administration approved the use of lanadelumab in August 2018, for people that are 12 years and older and have either type I or type II ...
A cerebroprotectant (formerly known as a neuroprotectant) is a drug that is intended to protect the brain after the onset of acute ischemic stroke. [1] As stroke is the second largest cause of death worldwide and a leading cause of adult disability, over 150 drugs have been tested in clinical trials to provide cerebroprotection.
However streptomycin is approved for this purpose only by the US Food and Drug Administration. [medical citation needed] In veterinary medicine, streptomycin is the first-line antibiotic for use against gram negative bacteria in large animals (horses, cattle, sheep, etc.). It is commonly combined with procaine penicillin for intramuscular ...
Antiserum or drug treatment should be stopped as soon as possible. [2] [3] Once treatment has stopped, symptoms usually resolve within seven days. [3] Outcomes are generally good. [4] Corticosteroids, antihistamines, and analgesics are the main line of treatment. [3] The choice depends on the severity of the reaction. Prednisone may be used in ...
[6] [3] Other side effects may include hypersensitivity reactions. [6] Galcanezumab was developed by Eli Lilly. [8] It was approved for medical use in the United States and in the European Union in 2018, [9] [10] [3] becoming the third calcitonin gene-related peptide (CGRP) inhibitor to be approved by the US Food and Drug Administration (FDA). [11]
Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [10] It was developed by Biogen and Eisai. [11] Aducanumab is given via intravenous infusion. [5] Aducanumab was ...